Unlock instant, AI-driven research and patent intelligence for your innovation.
SARS-CoV-2 coronavirus vaccine and preparation method thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A coronavirus, sars-cov-2 technology, applied in the field of biological genetic engineering, to achieve the effect of high biological activity, long-lasting immunogenicity and long half-life
Active Publication Date: 2021-04-09
GUANGZHOU DOUBLLE BIOPRODUCT CO LTD
View PDF17 Cites 13 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0009] At present, there is no research report on the preparation of a vaccine against SARS-CoV-2 viral S protein truncated by adenoviral vector
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0068] The construction of embodiment 1SARS-CoV-2 coronavirus vaccine Ad / S1
[0070] Using the S gene obtained in the basic example as a template, amplify with the following primers:
[0071] V1 (SEQ ID NO: 1): TCC CCCGGG ATGTTCGTCTTCCTGGTCCT
[0072] V4 (SEQ ID NO: 4): CCC AAGCTT TTACCGGGCTCTTCTGGGAGAGT
[0073] The S1 gene is amplified, that is, the positions 1-2055 of the S gene of the basic example, and the amplified product is named S1.
[0074] (2) Construction of recombinant plasmids:
[0075] The S1 fragment of the PCR amplification product obtained above was identified by gel running and recovered by gel cutting, and digested with SmaI and HindIII at 37°C. Digest pShuttle with these two enzymes at the same time. Next, use T4 ligase to ligate the digested PCR product with pShuttle overnight at 16°C. The ligation product was transformed into Escherichia coli DH5α, positive clones were screened by ampicillin res...
Embodiment 2
[0078] The construction of embodiment 2SARS-CoV-2 coronavirus vaccine Ad / S1N
[0079] The difference with Example 1 is: the PCR amplification primers used in step (1) are:
[0080] V1 (SEQ ID NO: 1): TCC CCCGGG ATGTTCGTCTTCCTGGTCCT
[0081] V3 (SEQ ID NO: 3): CCC AAGCTT TTAGGCCACCTGGTTGCTTGTAT
[0082] The rest is the same.
[0083] The amplified product is named S1N fragment, and the final SARS-CoV-2 vaccine is named Ad / S1N vaccine, and the inserted gene is sequenced, and the sequencing results are shown in Figure 4 .
Embodiment 3
[0084] The construction of embodiment 3SARS-CoV-2 coronavirus vaccine Ad / S1C
[0085] The difference with Example 1 is: the PCR amplification primers used in step (1) are:
[0086] V2 (SEQ ID NO: 2): TCC CCCGGG ATGAGGGTGCAGCCAACCGAG
[0087] V4 (SEQ ID NO: 4): CCC AAGCTT TTACCGGGCTCTTCTGGGAGAGT
[0088] The rest is the same.
[0089] The amplified product is named S1C fragment, and the final SARS-CoV-2 vaccine is named Ad / S1C vaccine, and the inserted gene is sequenced, and the sequencing results are shown in Figure 5 .
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention discloses a SARS-CoV-2 coronavirus vaccine and a preparation method thereof. An S gene of a SARS-CoV-2 coronavirus is subjected to codon optimization, truncated body and mutant sequences of the S gene are introduced into a secretory defective adenovirus vector, and packaging is conducted to obtain a corresponding recombinant adenovirus; and the recombinant adenovirus can express SARS-CoV-2 virus related proteinin vivo, processing, folding, glycosylation and other modifications are completed, the native conformation of S protein is basically maintained, and the characteristics of high biological activity, long half-life period, lasting immunogenicity and the like are achieved. According to the vaccine and the method, by adopting the defective adenovirus vector carrying secretory peptide, a recombinant adenovirus vaccine can be secreted out of cells after being expressed in vivo, so that the humoral immunity is activated.
Description
technical field [0001] The invention belongs to the field of biological genetic engineering, in particular to a SARS-CoV-2 coronavirus vaccine. Background technique [0002] The new coronavirus has a strong ability to spread from person to person, and the transmission index R0 is about 2.5. The virus mainly infects people through the respiratory tract or contact transmission. It can cause acute pneumonia and can also cause serious damage to other systems such as the urinary system, digestive system and nervous system. Currently, there is no effective drug treatment. Therefore, it is very important to design and develop an effective vaccine against this virus. [0003] In addition, the SARS-CoV-2 coronavirus is a single-stranded RNA virus, which is very unstable. It is subject to immune supervision and rejection in somatic cells, and it is very prone to mutations. Therefore, vaccines designed based on antigenic determinants with relatively conserved sequences can induce rel...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More 
